rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2025-432-442rsp-3803Research ArticleПРОГРЕСС В РЕВМАТОЛОГИИ В XXI ВЕКЕPROGRESS IN RHEUMATOLOGY IN THE XXI CENTURYСывороточный кальпротектин при иммуновоспалительных ревматических заболеваниях: новый биомаркер воспаленияSerum calprotectin in immune-mediated inflammatory rheumatic diseases: a new biomarker of inflammationhttps://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

Насонов Евгений Львович 

115522, Москва, Каширское шоссе, 34а

Evgeny L. Nasonov 

115522, Moscow, Kashirskoye Highway, 34A

nasonov@irramn.ruhttps://orcid.org/0000-0003-3057-9175АвдееваА. С.AvdeevaA. S.

115522, Москва, Каширское шоссе, 34а

Anastasia S. Avdeeva 

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0001-7847-1679БарановА. А.BaranovA. A.

150000, Ярославль, ул. Революционная, 5

Andrey A. Baranov 

150000, Yaroslavl, Revolyutsionnaya str., 5

https://orcid.org/0000-0003-2685-1623СамсоновМ. Ю.SamsonovM. Yu.

119421, Москва, Ленинский просп., 111

Mikhail Yu. Samsonov 

119421, Moscow, Leninsky avenue, 111

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава РоссииРоссияYaroslavl State Medical UniversityRussian FederationАО «Р-ФАРМ»РоссияR-Pharm, JSCRussian Federation202501112025635432442Copyright © Насонов Е.Л., Авдеева А.С., Баранов А.А., Самсонов М.Ю., 20252025Насонов Е.Л., Авдеева А.С., Баранов А.А., Самсонов М.Ю.Nasonov E.L., Avdeeva A.S., Baranov A.A., Samsonov M.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3803

При иммуновоспалительных ревматических заболеваниях (ИВРЗ) лабораторные биомаркеры, к которым относятся аутоантитела, белки острой фазы воспаления, цитокины, маркеры повреждения эндотелия, компоненты системы комплемента, субпопуляции лимфоцитов, показатели костного метаболизма и многие другие, занимают центральное место в диагностике, оценке активности и мониторинге эффективности фармакотерапии. В спектре биомаркеров воспаления в последние годы особое внимание привлечено к кальпротектину (КП), представляющему собой гетеродимерный комплекс S100A8 и S100A9 кальций-зависимых белков. В настоящее время для характеристики воспаления при ИВРЗ привлекает внимание определение концентрации КП в биологических жидкостях – так называемого циркулирующего или сывороточного (с) КП, увеличение концентрации которого может быть в большей степени связано с локальным (in situ), чем с системным, синтезом КП. В нарративном обзоре суммированы данные, касающиеся клинического значения определения сКП при ревматоидном артрите и других ИВРЗ как нового биомаркера активности воспаления. Представлены предварительные рекомендации, касающиеся показаний к определению сКП при ИВРЗ.

In immuno-mediated rheumatic diseases (IMRD), laboratory biomarkers, which include autoantibodies, proteins of the acute phase of inflammation, cytokines, markers of endothelial damage, components of the complement system, subpopulations of lymphocytes, indicators of bone metabolism, and many others, occupy a central place in the diagnosis, assessment of activity, and monitoring of the effectiveness of pharmacotherapy. In the range of biomarkers of inflammation in recent years, special attention has been drawn to calprotectin (CP), which is a heterodimeric complex of S100A8 and S100A9 calcium-dependent proteins. Currently, to characterize inflammation in IMRD, attention is drawn to determining the concentration of CP in biological fluids, the so-called circulating or serum (s) CP, an increase in the concentration of which may be more associated with local (in situ) than with systemic synthesis of protein. The narrative review summarizes the clinical significance of the sCP determination in IMRD as a new biomarker of inflammation. Preliminary recommendations regarding indications for determining the sCP in IMRD are presented.

иммуновоспалительные ревматические заболеваниякальпротектинС-реактивный белокинтерлейкин 6immuno-mediated rheumatic diseasescalprotectinC-reactive proteininterleukin 6ReferencesНасонов ЕЛ, Баранов АА, Авдеева АС, Левшин НЮ, Лапкина НА, Абайтова НЕ, и др. Лабораторная диагностика иммуновоспалительных ревматических заболеваний. В: Долгов ВВ, Годков МА, Вавилова ТВ (ред.). Клиническая лабораторная диагностика. Национальное руководство. М.:ГЭОТАРМедиа;2025:557-602.Nasonov EL, Baranov AA, Avdeeva AS, Levshin NYu, Lapkina NA, Abaitova NE, et al. Laboratory diagnostics of immune-inflammatory rheumatic diseases. In: Dolgov VV, Godkov MA, Vavilova TV (eds.). Clinical laboratory diagnostics. National guidelines. Moscow:GEOTAR-Media;2025:557-602 (In Russ.).Colina M, Campana G. Precision medicine in rheumatology: The role of biomarkers in diagnosis and treatment optimization. J Clin Med. 2025;14(5):1735. doi: 10.3390/jcm14051735Colina M, Campana G. Precision medicine in rheumatology: The role of biomarkers in diagnosis and treatment optimization. J Clin Med. 2025;14(5):1735. doi: 10.3390/jcm14051735Avouac J, Kay J, Choy E. Personalised treatment of rheumatoid arthritis based on cytokine profiles and synovial tissue signatures: Potentials and challenges. Semin Arthritis Rheum. 2025;73:152740. doi: 10.1016/j.semarthrit.2025.152740Avouac J, Kay J, Choy E. Personalised treatment of rheumatoid arthritis based on cytokine profiles and synovial tissue signatures: Potentials and challenges. Semin Arthritis Rheum. 2025;73:152740. doi: 10.1016/j.semarthrit.2025.152740Sahin D, Di Matteo A, Emery P. Biomarkers in the diagnosis, prognosis and management of rheumatoid arthritis: A comprehensive review. Ann Clin Biochem. 2025;62(1):3-21. doi: 10.1177/00045632241285843Sahin D, Di Matteo A, Emery P. Biomarkers in the diagnosis, prognosis and management of rheumatoid arthritis: A comprehensive review. Ann Clin Biochem. 2025;62(1):3-21. doi: 10.1177/00045632241285843Насонов ЕЛ. Современная концепция аутоиммунитета в ревматологии. Научно-практическая ревматология. 2023;61(4):397-420. doi: 10.47360/1995-4484-2023-397-420Nasonov E.L. Modern concept of autoimmunity in rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(4):397-420 (In Russ.). doi: 10.47360/1995-4484-2023-397-420Насонов ЕЛ, Александрова ЕН, Новиков АА. Аутоиммунные ревматические заболевания – проблемы иммунопатологии и персонифицированной терапии. Вестник РАМН. 2015;70(2):169-182. doi: 10.15690/vramn.v70i2.1310Nasonov EL, Aleksandrova EN, Novikov AA. Autoimmune rheumatic diseases – problems of immunopathology and personalized treatment. Annals of the Russian Academy of Medical Sciences. 2015;70(2):169-182 (In Russ.). doi: 10.15690/vramn.v70i2.1310Szekanecz Z, McInnes IB, Schett G, Szamosi S, Benkő S, Szűcs G. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17(10):585-595. doi: 10.1038/s41584-021-00652-9Szekanecz Z, McInnes IB, Schett G, Szamosi S, Benkő S, Szűcs G. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17(10):585-595. doi: 10.1038/s41584-021-00652-9Mohan C, Assassi S. Biomarkers in rheumatic diseases: How can they facilitate diagnosis and assessment of disease activity? BMJ. 2015;351:h5079. doi: 10.1136/bmj.h5079Mohan C, Assassi S. Biomarkers in rheumatic diseases: How can they facilitate diagnosis and assessment of disease activity? BMJ. 2015;351:h5079. doi: 10.1136/bmj.h5079Giacomelli R, Afeltra A, Alunno A, Bartoloni-Bocci E, Berardicurti O, Bombardieri M, et al. Guidelines for biomarkers in autoimmune rheumatic diseases – evidence based analysis. Autoimmun Rev. 2019;18(1):93-106. doi: 10.1016/j.autrev.2018.08.003Giacomelli R, Afeltra A, Alunno A, Bartoloni-Bocci E, Berardicurti O, Bombardieri M, et al. Guidelines for biomarkers in autoimmune rheumatic diseases – evidence based analysis. Autoimmun Rev. 2019;18(1):93-106. doi: 10.1016/j.autrev.2018.08.003Авдеева АС. Клиническое значение кальпротектина при ревматических заболеваниях. Научно-практическая ревматология. 2018;56(4):494-499. doi: 10.14412/1995-4484-2018-494-499Avdeeva AS. Clinical significance of calprotectin in rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56(4):494-499 (In Russ.). doi: 10.14412/1995-4484-2018-494-499Romand X, Bernardy C, Nguyen MVC, Courtier A, Trocme C, Clapasson M, et al. Systemic calprotectin and chronic inflammatory rheumatic diseases. Joint Bone Spine. 2019;86(6):691-698. doi: 10.1016/j.jbspin.2019.01.003Romand X, Bernardy C, Nguyen MVC, Courtier A, Trocme C, Clapasson M, et al. Systemic calprotectin and chronic inflammatory rheumatic diseases. Joint Bone Spine. 2019;86(6):691-698. doi: 10.1016/j.jbspin.2019.01.003Carnazzo V, Redi S, Basile V, Natali P, Gulli F, Equitani F, et al. Calprotectin: Two sides of the same coin. Rheumatology (Oxford). 2024;63(1):26-33. doi: 10.1093/rheumatology/kead405Carnazzo V, Redi S, Basile V, Natali P, Gulli F, Equitani F, et al. Calprotectin: Two sides of the same coin. Rheumatology (Oxford). 2024;63(1):26-33. doi: 10.1093/rheumatology/kead405Manfredi M, Van Hoovels L, Benucci M, De Luca R, Coccia C, Bernardini P, et al. Circulating calprotectin (cCLP) in autoimmune diseases. Autoimmun Rev. 2023;22(5):103295. doi: 10.1016/j.autrev.2023.103295Manfredi M, Van Hoovels L, Benucci M, De Luca R, Coccia C, Bernardini P, et al. Circulating calprotectin (cCLP) in autoimmune diseases. Autoimmun Rev. 2023;22(5):103295. doi: 10.1016/j.autrev.2023.103295Inciarte-Mundo J, Frade-Sosa B, Sanmartí R. From bench to bedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis. Front Immunol. 2022;13:1001025. doi: 10.3389/fimmu.2022.1001025Inciarte-Mundo J, Frade-Sosa B, Sanmartí R. From bench to bedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis. Front Immunol. 2022;13:1001025. doi: 10.3389/fimmu.2022.1001025Wu YY, Li XF, Wu S, Niu XN, Yin SQ, Huang C, et al. Role of the S100 protein family in rheumatoid arthritis. Arthritis Res Ther. 2022;24(1):35. doi: 10.1186/s13075-022-02727-8Wu YY, Li XF, Wu S, Niu XN, Yin SQ, Huang C, et al. Role of the S100 protein family in rheumatoid arthritis. Arthritis Res Ther. 2022;24(1):35. doi: 10.1186/s13075-022-02727-8Wang X, Luo Y, Zhou Q, Ma J. The roles of S100A8/A9 and S100A12 in autoimmune diseases: Mechanisms, biomarkers, and therapeutic potential. Autoimmun Rev. 2025 Aug 26:103920. doi: 10.1016/j.autrev.2025.103920Wang X, Luo Y, Zhou Q, Ma J. The roles of S100A8/A9 and S100A12 in autoimmune diseases: Mechanisms, biomarkers, and therapeutic potential. Autoimmun Rev. 2025 Aug 26:103920. doi: 10.1016/j.autrev.2025.103920Насонов ЕЛ, Авдеева АС, Решетняк ТМ, Алексанкин АП, Рубцов ЮП. Роль нетоза в патогенезе иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2023;61(5):513-530. doi: 10.47360/1995-4484-2023-513-530Nasonov EL, Avdeeva AS, Reshetnyak TM, Aleksankin AP, Rubtsov YuP. The role of NETosis in the pathogenesis of immunoinflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(5):513-530 (In Russ.). doi: 10.47360/1995-4484-2023-513-530Wang W, Cao W, Zhang S, Chen D, Liu L. The role of calprotectin in the diagnosis and treatment of inflammatory bowel disease. Int J Mol Sci. 2025;26(5):1996. doi: 10.3390/ijms26051996Wang W, Cao W, Zhang S, Chen D, Liu L. The role of calprotectin in the diagnosis and treatment of inflammatory bowel disease. Int J Mol Sci. 2025;26(5):1996. doi: 10.3390/ijms26051996Massa B, Mylemans M, Cruessen BV, Infantino M, Bossuyt X, Van Hoovels L, et al. Circulating calprotectin in rheumatoid arthritis: Unravelling the impact of (pre-)analytical confounders on meta-analysis results. J Lab Pres Med. 2024;(9):13.Massa B, Mylemans M, Cruessen BV, Infantino M, Bossuyt X, Van Hoovels L, et al. Circulating calprotectin in rheumatoid arthritis: Unravelling the impact of (pre-)analytical confounders on meta-analysis results. J Lab Pres Med. 2024;(9):13.Nevejan L, Mylemans M, Vander Cruyssen B, Stubbe M, Van Den Bremt S, Hofman L, et al. Pre-analytical recommendations and reference values for circulating calprotectin are sample type and assay dependent. Clin Chem Lab Med. 2021;60(2):e57- e60. doi: 10.1515/cclm-2021-0998Nevejan L, Mylemans M, Vander Cruyssen B, Stubbe M, Van Den Bremt S, Hofman L, et al. Pre-analytical recommendations and reference values for circulating calprotectin are sample type and assay dependent. Clin Chem Lab Med. 2021;60(2):e57- e60. doi: 10.1515/cclm-2021-0998Mylemans M, Nevejan L, Van Den Bremt S, Stubbe M, Cruyssen BV, Moulakakis C, et al. Circulating calprotectin as biomarker in neutrophil-related inflammation: Pre-analytical recommendations and reference values according to sample type. Clin Chim Acta. 2021;517:149-155. doi: 10.1016/j.cca.2021.02.022Mylemans M, Nevejan L, Van Den Bremt S, Stubbe M, Cruyssen BV, Moulakakis C, et al. Circulating calprotectin as biomarker in neutrophil-related inflammation: Pre-analytical recommendations and reference values according to sample type. Clin Chim Acta. 2021;517:149-155. doi: 10.1016/j.cca.2021.02.022Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. doi: 10.1002/art.27584Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. doi: 10.1002/art.27584Orr CK, Najm A, Young F, McGarry T, Biniecka M, Fearon U, et al. The utility and limitations of CRP, ESR and DAS28-CRP in appraising disease activity in rheumatoid arthritis. Front Med (Lausanne). 2018;5:185. doi: 10.3389/fmed.2018.00185Orr CK, Najm A, Young F, McGarry T, Biniecka M, Fearon U, et al. The utility and limitations of CRP, ESR and DAS28-CRP in appraising disease activity in rheumatoid arthritis. Front Med (Lausanne). 2018;5:185. doi: 10.3389/fmed.2018.00185Kay J, Morgacheva O, Messing SP, Kremer JM, Greenberg JD, Reed GW, et al. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: Acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther. 2014;16(1):R40. doi: 10.1186/ar4469Kay J, Morgacheva O, Messing SP, Kremer JM, Greenberg JD, Reed GW, et al. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: Acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther. 2014;16(1):R40. doi: 10.1186/ar4469Sokka T, Pincus T. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%- 45% of patients with rheumatoid arthritis seen between 1980 and 2004: Analyses from Finland and the United States. J Rheumatol. 2009;36(7):1387-1390. doi: 10.3899/jrheum.080770Sokka T, Pincus T. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%- 45% of patients with rheumatoid arthritis seen between 1980 and 2004: Analyses from Finland and the United States. J Rheumatol. 2009;36(7):1387-1390. doi: 10.3899/jrheum.080770Mouliou DS. C-reactive protein: Pathophysiology, diagnosis, false test results and a novel diagnostic algorithm for clinicians. Diseases. 2023;11(4):132. doi: 10.3390/diseases11040132Mouliou DS. C-reactive protein: Pathophysiology, diagnosis, false test results and a novel diagnostic algorithm for clinicians. Diseases. 2023;11(4):132. doi: 10.3390/diseases11040132Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. doi: 10.1101/cshperspect.a016295Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. doi: 10.1101/cshperspect.a016295Pope JE, Choy EH. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheum. 2021;51(1):219-229. doi: 10.1016/j.semarthrit.2020.11.005Pope JE, Choy EH. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheum. 2021;51(1):219-229. doi: 10.1016/j.semarthrit.2020.11.005Bradford CM, McDonnell T, Raj D, Robinson GA, Cole A, Ramakrishnan S, et al. Characterization of a subset of patients with rheumatoid arthritis for whom current management strategies are inadequate. ACR Open Rheumatol. 2019;1(3):145-155. doi: 10.1002/acr2.1021Bradford CM, McDonnell T, Raj D, Robinson GA, Cole A, Ramakrishnan S, et al. Characterization of a subset of patients with rheumatoid arthritis for whom current management strategies are inadequate. ACR Open Rheumatol. 2019;1(3):145-155. doi: 10.1002/acr2.1021Lewis MJ, Çubuk C, Surace AEA, Sciacca E, Lau R, Goldmann K, et al.; STRAP collaborative group. Deep molecular profiling of synovial biopsies in the STRAP trial identifies signatures predictive of treatment response to biologic therapies in rheumatoid arthritis. Nat Commun. 2025;16(1):5374. doi: 10.1038/s41467-025-60987-9Lewis MJ, Çubuk C, Surace AEA, Sciacca E, Lau R, Goldmann K, et al.; STRAP collaborative group. Deep molecular profiling of synovial biopsies in the STRAP trial identifies signatures predictive of treatment response to biologic therapies in rheumatoid arthritis. Nat Commun. 2025;16(1):5374. doi: 10.1038/s41467-025-60987-9Rivellese F, Pontarini E, Fossati-Jimack L, Moura RA, Romão VC, Fonseca JE, et al.; Pathobiology of Early Arthritis Cohort (PEAC) investigators. Comparative Analysis of circulating and synovial immune cells in early untreated rheumatoid arthritis and their relationship with molecular pathology and disease outcomes. Arthritis Rheumatol. 2025 Apr 27. doi: 10.1002/art.43194Rivellese F, Pontarini E, Fossati-Jimack L, Moura RA, Romão VC, Fonseca JE, et al.; Pathobiology of Early Arthritis Cohort (PEAC) investigators. Comparative Analysis of circulating and synovial immune cells in early untreated rheumatoid arthritis and their relationship with molecular pathology and disease outcomes. Arthritis Rheumatol. 2025 Apr 27. doi: 10.1002/art.43194Baillet A, Trocmé C, Berthier S, Arlotto M, Grange L, Chenau J, et al. Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. Rheumatology (Oxford). 2010;49(4):671-682. doi: 10.1093/rheumatology/kep452Baillet A, Trocmé C, Berthier S, Arlotto M, Grange L, Chenau J, et al. Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. Rheumatology (Oxford). 2010;49(4):671-682. doi: 10.1093/rheumatology/kep452Kang KY, Woo JW, Park SH. S100A8/A9 as a biomarker for synovial inflammation and joint damage in patients with rheumatoid arthritis. Korean J Intern Med. 2014;29(1):12-19. doi: 10.3904/kjim.2014.29.1.12Kang KY, Woo JW, Park SH. S100A8/A9 as a biomarker for synovial inflammation and joint damage in patients with rheumatoid arthritis. Korean J Intern Med. 2014;29(1):12-19. doi: 10.3904/kjim.2014.29.1.12Brun JG, Haga HJ, Bøe E, Kallay I, Lekven C, Berntzen HB, et al. Calprotectin in patients with rheumatoid arthritis: Relation to clinical and laboratory variables of disease activity. J Rheumatol. 1992;19(6):859-862.Brun JG, Haga HJ, Bøe E, Kallay I, Lekven C, Berntzen HB, et al. Calprotectin in patients with rheumatoid arthritis: Relation to clinical and laboratory variables of disease activity. J Rheumatol. 1992;19(6):859-862.de Seny D, Fillet M, Ribbens C, Marée R, Meuwis MA, Lutteri L, et al. Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis. Clin Chem. 2008;54(6):1066-1075. doi: 10.1373/clinchem.2007.099549de Seny D, Fillet M, Ribbens C, Marée R, Meuwis MA, Lutteri L, et al. Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis. Clin Chem. 2008;54(6):1066-1075. doi: 10.1373/clinchem.2007.099549García-Arias M, Pascual-Salcedo D, Ramiro S, Ueberschlag ME, Jermann TM, Cara C, et al. Calprotectin in rheumatoid arthritis: Association with disease activity in a cross-sectional and a longitudinal cohort. Mol Diagn Ther. 2013;17(1):49-56. doi: 10.1007/s40291-013-0016-9García-Arias M, Pascual-Salcedo D, Ramiro S, Ueberschlag ME, Jermann TM, Cara C, et al. Calprotectin in rheumatoid arthritis: Association with disease activity in a cross-sectional and a longitudinal cohort. Mol Diagn Ther. 2013;17(1):49-56. doi: 10.1007/s40291-013-0016-9Hammer HB, Odegard S, Fagerhol MK, Landewé R, van der Heijde D, Uhlig T, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis. 2007;66(8):1093-1097. doi: 10.1136/ard.2006.064741Hammer HB, Odegard S, Fagerhol MK, Landewé R, van der Heijde D, Uhlig T, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis. 2007;66(8):1093-1097. doi: 10.1136/ard.2006.064741Chen YS, Yan W, Geczy CL, Brown MA, Thomas R. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther. 2009;11(2):R39. doi: 10.1186/ar2645Chen YS, Yan W, Geczy CL, Brown MA, Thomas R. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther. 2009;11(2):R39. doi: 10.1186/ar2645Hammer HB, Ødegård S, Syversen SW, Landewé R, van der Heijde D, Uhlig T, et al. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69(1):150-154. doi: 10.1136/ard.2008.103739Hammer HB, Ødegård S, Syversen SW, Landewé R, van der Heijde D, Uhlig T, et al. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69(1):150-154. doi: 10.1136/ard.2008.103739Inciarte-Mundo J, Ruiz-Esquide V, Hernández MV, Cañete JD, Cabrera-Villalba SR, Ramirez J, et al. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Rheumatology (Oxford). 2015;54(12):2239-2243. doi: 10.1093/rheumatology/kev251Inciarte-Mundo J, Ruiz-Esquide V, Hernández MV, Cañete JD, Cabrera-Villalba SR, Ramirez J, et al. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Rheumatology (Oxford). 2015;54(12):2239-2243. doi: 10.1093/rheumatology/kev251Andrés Cerezo L, Mann H, Pecha O, Pleštilová L, Pavelka K, Vencovský J, et al. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther. 2011;13(4):R122. doi: 10.1186/ar3426Andrés Cerezo L, Mann H, Pecha O, Pleštilová L, Pavelka K, Vencovský J, et al. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther. 2011;13(4):R122. doi: 10.1186/ar3426Jonsson MK, Sundlisæter NP, Nordal HH, Hammer HB, Aga AB, Olsen IC, et al. Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis. Ann Rheum Dis. 2017;76(12):2031-2037. doi: 10.1136/annrheumdis-2017-211695Jonsson MK, Sundlisæter NP, Nordal HH, Hammer HB, Aga AB, Olsen IC, et al. Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis. Ann Rheum Dis. 2017;76(12):2031-2037. doi: 10.1136/annrheumdis-2017-211695Bach M, Moon J, Moore R, Pan T, Nelson JL, Lood C. A neutrophil activation biomarker panel in prognosis and monitoring of patients with rheumatoid arthritis. Arthritis Rheumatol. 2020;72(1):47-56. doi: 10.1002/art.41062Bach M, Moon J, Moore R, Pan T, Nelson JL, Lood C. A neutrophil activation biomarker panel in prognosis and monitoring of patients with rheumatoid arthritis. Arthritis Rheumatol. 2020;72(1):47-56. doi: 10.1002/art.41062Wang Y, Liang Y. Clinical significance of serum calprotectin level for the disease activity in active rheumatoid arthritis with normal C-reactive protein. Int J Clin Exp Pathol. 2019;12(3):1009-1014.Wang Y, Liang Y. Clinical significance of serum calprotectin level for the disease activity in active rheumatoid arthritis with normal C-reactive protein. Int J Clin Exp Pathol. 2019;12(3):1009-1014.Torgutalp M, Yayla ME, Eroglu DS, Dincer ABK, Yurteri EU, Okatan IE, et al. Serum calprotectin is indicating clinical and ultrasonographic disease activity in rheumatoid arthritis, even with normal C-reactive protein levels. Mediterr J Rheumatol. 2021;32(1):56-65. doi: 10.31138/mjr.32.1.56Torgutalp M, Yayla ME, Eroglu DS, Dincer ABK, Yurteri EU, Okatan IE, et al. Serum calprotectin is indicating clinical and ultrasonographic disease activity in rheumatoid arthritis, even with normal C-reactive protein levels. Mediterr J Rheumatol. 2021;32(1):56-65. doi: 10.31138/mjr.32.1.56Inciarte-Mundo J, Victoria Hernández M, Ruiz-Esquide V, Raquel Cabrera-Villalba S, Ramirez J, Cuervo A, et al. Serum calprotectin versus acute-phase reactants in the discrimination of inflammatory disease activity in rheumatoid arthritis patients receiving tumor necrosis factor inhibitors. Arthritis Care Res (Hoboken). 2016;68(7):899-906. doi: 10.1002/acr.22795Inciarte-Mundo J, Victoria Hernández M, Ruiz-Esquide V, Raquel Cabrera-Villalba S, Ramirez J, Cuervo A, et al. Serum calprotectin versus acute-phase reactants in the discrimination of inflammatory disease activity in rheumatoid arthritis patients receiving tumor necrosis factor inhibitors. Arthritis Care Res (Hoboken). 2016;68(7):899-906. doi: 10.1002/acr.22795Inciarte-Mundo J, Ramirez J, Hernández MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, et al. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: A 1-year prospective cohort study. Arthritis Res Ther. 2018;20(1):275. doi: 10.1186/s13075-018-1764-zInciarte-Mundo J, Ramirez J, Hernández MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, et al. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: A 1-year prospective cohort study. Arthritis Res Ther. 2018;20(1):275. doi: 10.1186/s13075-018-1764-zSakellariou G, Lombardi G, Vitolo B, Gomarasca M, Faraldi M, Caporali R, et al. Serum calprotectin as a marker of ultrasounddetected synovitis in early psoriatic and rheumatoid arthritis: Results from a cross-sectional retrospective study. Clin Exp Rheumatol. 2019;37(3):429-436.Sakellariou G, Lombardi G, Vitolo B, Gomarasca M, Faraldi M, Caporali R, et al. Serum calprotectin as a marker of ultrasounddetected synovitis in early psoriatic and rheumatoid arthritis: Results from a cross-sectional retrospective study. Clin Exp Rheumatol. 2019;37(3):429-436.Hurnakova J, Zavada J, Hanova P, Hulejova H, Klein M, Mann H, et al. Serum calprotectin (S100A8/9): An independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17(1):252. doi: 10.1186/s13075-015-0764-5Hurnakova J, Zavada J, Hanova P, Hulejova H, Klein M, Mann H, et al. Serum calprotectin (S100A8/9): An independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17(1):252. doi: 10.1186/s13075-015-0764-5Hurnakova J, Hulejova H, Zavada J, Hanova P, Komarc M, Mann H, et al. Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. PLoS One. 2017;12(8):e0183420. doi: 10.1371/journal.pone.0183420Hurnakova J, Hulejova H, Zavada J, Hanova P, Komarc M, Mann H, et al. Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. PLoS One. 2017;12(8):e0183420. doi: 10.1371/journal.pone.0183420Bernardy C, Lejeune S, Courtier A, Wendling D, Berenbaum F, Nguyen MVC, et al. Calprotectin alone is not sufficient to predict response to methotrexate in early ACR/EULAR 2010 rheumatoid arthritis: Analysis of the ESPOIR cohort. Joint Bone Spine. 2020;87(1):99-100. doi: 10.1016/j.jbspin.2019.07.001Bernardy C, Lejeune S, Courtier A, Wendling D, Berenbaum F, Nguyen MVC, et al. Calprotectin alone is not sufficient to predict response to methotrexate in early ACR/EULAR 2010 rheumatoid arthritis: Analysis of the ESPOIR cohort. Joint Bone Spine. 2020;87(1):99-100. doi: 10.1016/j.jbspin.2019.07.001Choi IY, Gerlag DM, Herenius MJ, Thurlings RM, Wijbrandts CA, Foell D, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(3):499-505. doi: 10.1136/annrheumdis-2013-203923Choi IY, Gerlag DM, Herenius MJ, Thurlings RM, Wijbrandts CA, Foell D, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(3):499-505. doi: 10.1136/annrheumdis-2013-203923Smith SL, Alexander S, Nair N, Viatte S, Eyre S, Hyrich KL, et al. Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis. Ann Rheum Dis. 2023;82(5):611-620. doi: 10.1136/ard-2022-222519Smith SL, Alexander S, Nair N, Viatte S, Eyre S, Hyrich KL, et al. Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis. Ann Rheum Dis. 2023;82(5):611-620. doi: 10.1136/ard-2022-222519Sejersen K, Weitoft T, Knight A, Lysholm J, Larsson A, Rönnelid J. Serum calprotectin correlates stronger with inflammation and disease activity in ACPA positive than ACPA negative rheumatoid arthritis. Rheumatology (Oxford). 2025;64(1):126-132. doi: 10.1093/rheumatology/kead641Sejersen K, Weitoft T, Knight A, Lysholm J, Larsson A, Rönnelid J. Serum calprotectin correlates stronger with inflammation and disease activity in ACPA positive than ACPA negative rheumatoid arthritis. Rheumatology (Oxford). 2025;64(1):126-132. doi: 10.1093/rheumatology/kead641Frade-Sosa B, Ponce A, Inciarte-Mundo J, Morlà R, Ruiz-Esquide V, Macías L, et al. Plasma calprotectin as a biomarker of ultrasound synovitis in rheumatoid arthritis patients receiving IL-6 antagonists or JAK inhibitors. Ther Adv Musculoskelet Dis. 2022;14:1759720X221114105. doi: 10.1177/1759720X221114105Frade-Sosa B, Ponce A, Inciarte-Mundo J, Morlà R, RuizEsquide V, Macías L, et al. Plasma calprotectin as a biomarker of ultrasound synovitis in rheumatoid arthritis patients receiving IL-6 antagonists or JAK inhibitors. Ther Adv Musculoskelet Dis. 2022;14:1759720X221114105. doi: 10.1177/1759720X221114105Frade-Sosa B, Ponce A, Ruiz-Ortiz E, De Moner N, Gómara MJ, Azuaga AB, et al. Neutrophilic activity biomarkers (plasma neutrophil extracellular traps and calprotectin) in established patients with rheumatoid arthritis receiving biological or JAK inhibitors: A clinical and ultrasonographic study. Rheumatol Ther. 2024;11(3):501-521. doi: 10.1007/s40744-024-00650-9Frade-Sosa B, Ponce A, Ruiz-Ortiz E, De Moner N, Gómara MJ, Azuaga AB, et al. Neutrophilic activity biomarkers (plasma neutrophil extracellular traps and calprotectin) in established patients with rheumatoid arthritis receiving biological or JAK inhibitors: A clinical and ultrasonographic study. Rheumatol Ther. 2024;11(3):501-521. doi: 10.1007/s40744-024-00650-9Nordal HH, Fagerhol MK, Halse AK, Hammer HB. Calprotectin (S100A8/A9) should preferably be measured in EDTA-plasma; results from a longitudinal study of patients with rheumatoid arthritis. Scand J Clin Lab Invest. 2018;78(1-2):102-108. doi: 10.1080/00365513.2017.1419371Nordal HH, Fagerhol MK, Halse AK, Hammer HB. Calprotectin (S100A8/A9) should preferably be measured in EDTA-plasma; results from a longitudinal study of patients with rheumatoid arthritis. Scand J Clin Lab Invest. 2018;78(1-2):102-108. doi: 10.1080/00365513.2017.1419371Bettner LF, Peterson RA, Bergstedt DT, Kelmenson LB, Demoruelle MK, Mikuls TR, et al. Combinations of anticyclic citrullinated protein antibody, rheumatoid factor, and serum calprotectin positivity are associated with the diagnosis of rheumatoid arthritis within 3 years. ACR Open Rheumatol. 2021;3(10):684-689. doi: 10.1002/acr2.11309Bettner LF, Peterson RA, Bergstedt DT, Kelmenson LB, Demoruelle MK, Mikuls TR, et al. Combinations of anticyclic citrullinated protein antibody, rheumatoid factor, and serum calprotectin positivity are associated with the diagnosis of rheumatoid arthritis within 3 years. ACR Open Rheumatol. 2021;3(10):684-689. doi: 10.1002/acr2.11309Inciarte-Mundo J, Ramirez J, Hernández MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, et al. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Arthritis Res Ther. 2016;18(1):160. doi: 10.1186/s13075-016-1032-zInciarte-Mundo J, Ramirez J, Hernández MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, et al. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Arthritis Res Ther. 2016;18(1):160. doi: 10.1186/s13075-016-1032-zStevens D, Sundbakk L, Kazemi A, Heiberg M, Sokka-Isler T, Gudbjornsson B, et al. Plasma calprotectin assessed in multiple biological treatment strategies for early rheumatoid arthritis over 48 weeks. Arthritis Rheumatol. 2024;76(Suppl 9). https://acrabstracts.org/abstract/plasma-calprotectin-assessed-in-multiple-biological-treatment-strategies-for-early-rheumatoid-arthritis-over-48-weeksStevens D, Sundbakk L, Kazemi A, Heiberg M, Sokka-Isler T, Gudbjornsson B, et al. Plasma calprotectin assessed in multiple biological treatment strategies for early rheumatoid arthritis over 48 weeks. Arthritis Rheumatol. 2024;76(Suppl 9). https://acrabstracts.org/abstract/plasma-calprotectin-assessed-in-multiple-biological-treatment-strategies-for-early-rheumatoid-arthritis-over-48-weeksАвдеева АС, Черкасова МВ, Насонов ЕЛ. Динамика уровня кальпротектина у пациентов с ревматоидным артритом на фоне терапии биоаналогом ритуксимаба (Ацеллбия «Биокад»). Научно-практическая ревматология. 2021;59(4): 401-405. doi: 10.47360/1995-4484-2021-401-405Avdeeva AS, Cherkasova MV, Nasonov EL. Dynamics of the level of calprotectin in patients with rheumatoid arthritis during rituximab biosimilar (Acellbia “Biocad”) therapy. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):401-405 (In Russ.). doi: 10.47360/1995-4484-2021-401-405Zeng J, Liu X, Liu J, Wu P, Yang L. Linkage of calprotectin with inflammation, activity and treatment response of rheumatoid arthritis: A meta-analysis. Biomark Med. 2022;16(17):1239-1249. doi: 10.2217/bmm-2022-0216Zeng J, Liu X, Liu J, Wu P, Yang L. Linkage of calprotectin with inflammation, activity and treatment response of rheumatoid arthritis: A meta-analysis. Biomark Med. 2022;16(17):1239-1249. doi: 10.2217/bmm-2022-0216Bae SC, Lee YH. Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: A meta-analysis. Postgrad Med. 2017;129(5):531-537. doi: 10.1080/00325481.2017.1319729Bae SC, Lee YH. Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: A meta-analysis. Postgrad Med. 2017;129(5):531-537. doi: 10.1080/00325481.2017.1319729Massa B, Mylemans M, Vander Cruyssen B, Infantino M, Bossuyt X, Van Hoovels L. Circulating calprotectin in rheumatoid arthritis: Unravelling the impact of (pre-)analytical confounders on meta-analysis results. J Lab Precis Med. 2024;9:13. doi: 10.21037/jlpm-23-79Massa B, Mylemans M, Vander Cruyssen B, Infantino M, Bossuyt X, Van Hoovels L. Circulating calprotectin in rheumatoid arthritis: Unravelling the impact of (pre-)analytical confounders on meta-analysis results. J Lab Precis Med. 2024;9:13. doi: 10.21037/jlpm-23-79Low A, Lim F, Ma M. A systematic review looking at the relationship between serum calprotectin and ultrasound parameters in rheumatoid arthritis. Arthritis Rheumatol. 2021;73(Suppl 9): https://acrabstracts.org/abstract/a-systematic-review-looking-at-the-relationshipbetween-serum-calprotectin-and-ultrasound-parameters-in-rheumatoid-arthritis/Low A, Lim F, Ma M. A systematic review looking at the relationship between serum calprotectin and ultrasound parameters in rheumatoid arthritis. Arthritis Rheumatol. 2021;73(Suppl 9): https://acrabstracts.org/abstract/a-systematic-review-looking-at-the-relationshipbetween-serum-calprotectin-and-ultrasound-parameters-in-rheumatoid-arthritis/Nordal HH, Brokstad KA, Solheim M, Halse AK, Kvien TK, Hammer HB. Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: Results from a longitudinal study of patients with established rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):3. doi: 10.1186/s13075-016-1201-0Nordal HH, Brokstad KA, Solheim M, Halse AK, Kvien TK, Hammer HB. Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: Results from a longitudinal study of patients with established rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):3. doi: 10.1186/s13075-016-1201-0Tweehuysen L, den Broeder N, van Herwaarden N, Joosten LAB, van Lent PL, Vogl T, et al. Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering antiTNF treatment in patients with rheumatoid arthritis. RMD Open. 2018;4(1):e000654. doi: 10.1136/rmdopen-2018-000654Tweehuysen L, den Broeder N, van Herwaarden N, Joosten LAB, van Lent PL, Vogl T, et al. Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering antiTNF treatment in patients with rheumatoid arthritis. RMD Open. 2018;4(1):e000654. doi: 10.1136/rmdopen-2018-000654Andres Cerezo L, Mann H, Pecha O, Plestilova L, Pavelka K, Vencovsky J, et al. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther. 2011;13(4):R122.Andres Cerezo L, Mann H, Pecha O, Plestilova L, Pavelka K, Vencovsky J, et al. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther. 2011;13(4):R122.Kuley R, Duvvuri B, Hasnain S, Dow ER, Koch AE, Higgs RE, et al. Neutrophil activation markers and rheumatoid arthritis Treatment response to the JAK1/2 inhibitor baricitinib. Arthritis Rheumatol. 2025;77(4):395-404. doi: 10.1002/art.43042Kuley R, Duvvuri B, Hasnain S, Dow ER, Koch AE, Higgs RE, et al. Neutrophil activation markers and rheumatoid arthritis Treatment response to the JAK1/2 inhibitor baricitinib. Arthritis Rheumatol. 2025;77(4):395-404. doi: 10.1002/art.43042Frade-Sosa B, Ponce A, Ruiz-Esquide V, García-Yébenes MJ, Morlá R, Sapena N, et al. High sensitivity C reactive protein in patients with rheumatoid arthritis treated with antibodies against IL-6 or JAK inhibitors: A clinical and ultrasonographic study. Diagnostics (Basel). 2022;12(1):182. doi: 10.3390/diagnostics12010182Frade-Sosa B, Ponce A, Ruiz-Esquide V, García-Yébenes MJ, Morlá R, Sapena N, et al. High sensitivity C reactive protein in patients with rheumatoid arthritis treated with antibodies against IL-6 or JAK inhibitors: A clinical and ultrasonographic study. Diagnostics (Basel). 2022;12(1):182. doi: 10.3390/diagnostics12010182Gernert M, Schmalzing M, Tony HP, Strunz PP, Schwaneck EC, Fröhlich M. Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy. Arthritis Res Ther. 2022;24(1):200. doi: 10.1186/s13075-022-02887-7Gernert M, Schmalzing M, Tony HP, Strunz PP, Schwaneck EC, Fröhlich M. Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy. Arthritis Res Ther. 2022;24(1):200. doi: 10.1186/s13075-022-02887-7Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants. Arthritis Rheum. 2011;63(1):43-52. doi: 10.1002/art.27740Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants. Arthritis Rheum. 2011;63(1):43-52. doi: 10.1002/art.27740Asai S, Takahashi N, Kobayakawa T, Kaneko A, Watanabe T, Kato T, et al. Comparison of the effects of baricitinib and tocili zumab on disease activity in patients with rheumatoid arthritis: A propensity score matching analysis. Clin Rheumatol. 2021;(8):3143-3151. doi: 10.1007/s10067-021-05815-3Asai S, Takahashi N, Kobayakawa T, Kaneko A, Watanabe T, Kato T, et al. Comparison of the effects of baricitinib and tocili zumab on disease activity in patients with rheumatoid arthritis: A propensity score matching analysis. Clin Rheumatol. 2021;(8):3143-3151. doi: 10.1007/s10067-021-05815-3Smolen JS, Aletaha D, Gruben D, Zwillich SH, Krishnaswami S, Mebus C. Brief report: Remission rates with tofacitinib treatment in rheumatoid arthritis: A comparison of various remission criteria. Arthritis Rheumatol. 2017;69(4):728-734. doi: 10.1002/art.39996Smolen JS, Aletaha D, Gruben D, Zwillich SH, Krishnaswami S, Mebus C. Brief report: Remission rates with tofacitinib treatment in rheumatoid arthritis: A comparison of various remission criteria. Arthritis Rheumatol. 2017;69(4):728-734. doi: 10.1002/art.39996Naredo E, Rodrigez M, Campos C, Rodríguez-Heredia JM, Medina JA, Giner E, et al. Validity, reproducibility, and responsiveness of a twelve-joint simplified power Doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. Athritis Rheum. 2008;59:515-522. doi: 10.1002/art.23529Naredo E, Rodrigez M, Campos C, Rodríguez-Heredia JM, Medina JA, Giner E, et al. Validity, reproducibility, and responsiveness of a twelve-joint simplified power Doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. Athritis Rheum. 2008;59:515-522. doi: 10.1002/art.23529Алексеева ОГ. Ультразвуковое исследование суставов при ревматоидном артрите: патогенетическая обоснованность, возможности использования в диагностике, оценке эффективности терапии и прогнозировании исходов. Научнопрактическая ревматология. 2018;56(1):82-92. doi: 10.14412/1995-4484-2018-82-92Alekseeva OG. Joint ultrasonography in rheumatoid arthritis: Pathogenetic rationale, possible use in diagnosis, therapy efficiency evaluation, and outcome prediction. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56(1):82-92 (In Russ.). doi: 10.14412/1995-4484-2018-82-92Ruscitti P, Cantarini L, Nigrovic PA, McGonagle D, Giacomelli R. Recent advances and evolving concepts in Still’s disease. Nat Rev Rheumatol. 2024;20(2):116-132. doi: 10.1038/s41584-023-01065-6Ruscitti P, Cantarini L, Nigrovic PA, McGonagle D, Giacomelli R. Recent advances and evolving concepts in Still’s disease. Nat Rev Rheumatol. 2024;20(2):116-132. doi: 10.1038/s41584-023-01065-6Насонов ЕЛ, Файст Е. Болезнь Стилла взрослых: новые горизонты. Научно-практическая ревматология. 2021;59(6):645- 665. doi: 10.47360/1995-4484-2021-643-663Nasonov EL, Feist E. Adult Still’s disease: New horizons. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(6):645-665 (In Russ.). doi: 10.47360/1995-4484-2021-643-663De Matteis A, Bindoli S, De Benedetti F, Carmona L, Fautrel B, Mitrovic S. Systemic juvenile idiopathic arthritis and adult-onset Still’s disease are the same disease: Evidence from systematic reviews and meta-analyses informing the 2023 EULAR/PReS recommendations for the diagnosis and management of Still’s disease. Ann Rheum Dis. 2024;83(12):1748-1761. doi: 10.1136/ard-2024-225853De Matteis A, Bindoli S, De Benedetti F, Carmona L, Fautrel B, Mitrovic S. Systemic juvenile idiopathic arthritis and adult-onset Still’s disease are the same disease: Evidence from systematic reviews and meta-analyses informing the 2023 EULAR/PReS recommendations for the diagnosis and management of Still’s disease. Ann Rheum Dis. 2024;83(12):1748-1761. doi: 10.1136/ard-2024-225853Codes-Méndez H, Magallares-López B, Park HS, Mariscal A, Juárez C, Boronat S, et al. Diagnostic accuracy of serum calprotectin measured by CLIA and EIA in juvenile idiopathic arthritis: A proof-of-concept study. Front Pediatr. 2024;12:1422916. doi: 10.3389/fped.2024.1422916Codes-Méndez H, Magallares-López B, Park HS, Mariscal A, Juárez C, Boronat S, et al. Diagnostic accuracy of serum calprotectin measured by CLIA and EIA in juvenile idiopathic arthritis: A proof-of-concept study. Front Pediatr. 2024;12:1422916. doi: 10.3389/fped.2024.1422916d’Angelo DM, Attanasi M, Di Donato G, Lapergola G, Flacco M, Chiarelli F, et al. The role of serum calprotectin in defining disease outcomes in non-systemic juvenile idiopathic arthritis: A pilot study. Int J Mol Sci. 2023;24(2):1671. doi: 10.3390/ijms24021671d’Angelo DM, Attanasi M, Di Donato G, Lapergola G, Flacco M, Chiarelli F, et al. The role of serum calprotectin in defining disease outcomes in non-systemic juvenile idiopathic arthritis: A pilot study. Int J Mol Sci. 2023;24(2):1671. doi: 10.3390/ijms24021671Romano M, Gerloni V, De Lucia O, Piskin D, Giani T, Gattinara M, et al. Serum calprotectin (S100A8/9), clinical and ultrasound assessment in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2021;39(5):1132-1140. doi: 10.55563/clinexprheumatol/5tckciRomano M, Gerloni V, De Lucia O, Piskin D, Giani T, Gattinara M, et al. Serum calprotectin (S100A8/9), clinical and ultrasound assessment in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2021;39(5):1132-1140. doi: 10.55563/clinexprheumatol/5tckciAljaberi N, Tronconi E, Schulert G, Grom AA, Lovell DJ, Huggins JL, et al. The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: A retrospective analysis. Pediatr Rheumatol Online J. 2020;18(1):7. doi: 10.1186/s12969-020-0398-2Aljaberi N, Tronconi E, Schulert G, Grom AA, Lovell DJ, Huggins JL, et al. The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: A retrospective analysis. Pediatr Rheumatol Online J. 2020;18(1):7. doi: 10.1186/s12969-020-0398-2Barendregt AM, Veldkamp SR, Hissink Muller PCE, van de Geer A, Aarts C, van Gulik EC, et al. MRP8/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). 2020;59(9):2392-2401. doi: 10.1093/rheumatology/kez590Barendregt AM, Veldkamp SR, Hissink Muller PCE, van de Geer A, Aarts C, van Gulik EC, et al. MRP8/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). 2020;59(9):2392-2401. doi: 10.1093/rheumatology/kez590Hinze CH, Foell D, Johnson AL, Spalding SJ, Gottlieb BS, Morris PW, et al. Serum S100A8/A9 and S100A12 levels in children with polyarticular forms of juvenile idiopathic arthritis: Relationship to maintenance of clinically inactive disease during anti-tumor necrosis factor therapy and occurrence of disease flare after discontinuation of therapy. Arthritis Rheumatol. 2019;71(3):451-459. doi: 10.1002/art.40727Hinze CH, Foell D, Johnson AL, Spalding SJ, Gottlieb BS, Morris PW, et al. Serum S100A8/A9 and S100A12 levels in children with polyarticular forms of juvenile idiopathic arthritis: Relationship to maintenance of clinically inactive disease during anti-tumor necrosis factor therapy and occurrence of disease flare after discontinuation of therapy. Arthritis Rheumatol. 2019;71(3):451-459. doi: 10.1002/art.40727La C, Lê PQ, Ferster A, Goffin L, Spruyt D, Lauwerys B, et al. Serum calprotectin (S100A8/A9): A promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis. RMD Open. 2021;7(2):e001646. doi: 10.1136/rmdopen-2021-001646La C, Lê PQ, Ferster A, Goffin L, Spruyt D, Lauwerys B, et al. Serum calprotectin (S100A8/A9): A promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis. RMD Open. 2021;7(2):e001646. doi: 10.1136/rmdopen-2021-001646Boyko Y, Ivanova V, Vakaruk M, Kozina T, Shevchenko N, Vaizer N, et al. Blood calprotectin in children with juvenile idiopathic arthritis: Relationship to flare development after discontinuation of treatment. Reumatologia. 2020;58(4):202-207. doi: 10.5114/reum.2020.98431Boyko Y, Ivanova V, Vakaruk M, Kozina T, Shevchenko N, Vaizer N, et al. Blood calprotectin in children with juvenile idiopathic arthritis: Relationship to flare development after discontinuation of treatment. Reumatologia. 2020;58(4):202-207. doi: 10.5114/reum.2020.98431Anink J, Van Suijlekom-Smit LW, Otten MH, Prince FH, van Rossum MA, Dolman KM, et al. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis Res Ther. 2015;17(1):200. doi: 10.1186/s13075-015-0723-1Anink J, Van Suijlekom-Smit LW, Otten MH, Prince FH, van Rossum MA, Dolman KM, et al. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis Res Ther. 2015;17(1):200. doi: 10.1186/s13075-015-0723-1Brunner HI, Schulert GS, Sproles A, Thornton S, Cornejo GV, Antón J, et al. S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Arthritis Res Ther. 2024;26(1):125. doi: 10.1186/s13075-024-03347-0Brunner HI, Schulert GS, Sproles A, Thornton S, Cornejo GV, Antón J, et al. S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Arthritis Res Ther. 2024;26(1):125. doi: 10.1186/s13075-024-03347-0Keskitalo PL, Kangas SM, Sard S, Pokka T, Glumoff V, Kulmala P, et al. Myeloid-related protein 8/14 in plasma and serum in patients with new-onset juvenile idiopathic arthritis in realworld setting in a single center. Pediatr Rheumatol Online J. 2022;20(1):42. doi: 10.1186/s12969-022-00701-xKeskitalo PL, Kangas SM, Sard S, Pokka T, Glumoff V, Kulmala P, et al. Myeloid-related protein 8/14 in plasma and serum in patients with new-onset juvenile idiopathic arthritis in realworld setting in a single center. Pediatr Rheumatol Online J. 2022;20(1):42. doi: 10.1186/s12969-022-00701-xSharma TK, Saxena S, Arora P, Sharma AK. S100A12 protein levels in juvenile idiopathic arthritis (JIA): A systematic review and meta-analysis. Clin Lab. 2025;71(5). doi: 10.7754/Clin.Lab.2024.241041Sharma TK, Saxena S, Arora P, Sharma AK. S100A12 protein levels in juvenile idiopathic arthritis (JIA): A systematic review and meta-analysis. Clin Lab. 2025;71(5). doi: 10.7754/Clin.Lab.2024.241041d’Angelo DM, Attanasi M, Di Donato G, Lapergola G, Cannataro G, Flacco M, et al. Serum calprotectin and joint ultrasound in the definition of disease relapse in non-systemic juvenile idiopathic arthritis: A prospective longitudinal study. Clin Exp Rheumatol. 2024;42(1):185-193. doi: 10.55563/clinexprheumatol/qumh2od’Angelo DM, Attanasi M, Di Donato G, Lapergola G, Cannataro G, Flacco M, et al. Serum calprotectin and joint ultrasound in the definition of disease relapse in non-systemic juvenile idiopathic arthritis: A prospective longitudinal study. Clin Exp Rheumatol. 2024;42(1):185-193. doi: 10.55563/clinexprheumatol/qumh2oFoell D, Saers M, Park C, Brix N, Glerup M, Kessel C, et al. A novel serum calprotectin (MRP8/14) particle-enhanced immuno-turbidimetric assay (sCAL turbo) helps to differentiate systemic juvenile idiopathic arthritis from other diseases in routine clinical laboratory settings. Mol Cell Pediatr. 2023;10(1):14. doi: 10.1186/s40348-023-00168-0Foell D, Saers M, Park C, Brix N, Glerup M, Kessel C, et al. A novel serum calprotectin (MRP8/14) particle-enhanced immuno-turbidimetric assay (sCAL turbo) helps to differentiate systemic juvenile idiopathic arthritis from other diseases in routine clinical laboratory settings. Mol Cell Pediatr. 2023;10(1):14. doi: 10.1186/s40348-023-00168-0Park C, Miranda-Garcia M, Berendes R, Horneff G, Kuemmerle-Deschner J, Ganser G, et al. MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever. Rheumatology (Oxford). 2022;61(7):3082- 3092. doi: 10.1093/rheumatology/keab729Park C, Miranda-Garcia M, Berendes R, Horneff G, KuemmerleDeschner J, Ganser G, et al. MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever. Rheumatology (Oxford). 2022;61(7):3082- 3092. doi: 10.1093/rheumatology/keab729Breda L, La Bella S, Di Ludovico A. Biomarkers in juvenile idiopathic arthritis: Towards precision diagnosis and personalized therapy? Curr Opin Rheumatol. 2025;37(5):308-315. doi: 10.1097/BOR.0000000000001109Breda L, La Bella S, Di Ludovico A. Biomarkers in juvenile idiopathic arthritis: Towards precision diagnosis and personalized therapy? Curr Opin Rheumatol. 2025;37(5):308-315. doi: 10.1097/BOR.0000000000001109Guo Q, Zha X, Li C, Jia Y, Zhu L, Guo J, et al. Serum calprotectin – a promising diagnostic marker for adult-onset Still’s disease. Clin Rheumatol. 2016;35(1):73-79. doi: 10.1007/s10067-015-3108-6Guo Q, Zha X, Li C, Jia Y, Zhu L, Guo J, et al. Serum calprotectin – a promising diagnostic marker for adult-onset Still’s disease. Clin Rheumatol. 2016;35(1):73-79. doi: 10.1007/s10067-015-3108-6Jung SY, Park YB, Ha YJ, Lee KH, Lee SK. Serum calprotectin as a marker for disease activity and severity in adult-onset Still’s disease. J Rheumatol. 2010;37(5):1029-1034. doi: 10.3899/jrheum.091120Jung SY, Park YB, Ha YJ, Lee KH, Lee SK. Serum calprotectin as a marker for disease activity and severity in adult-onset Still’s disease. J Rheumatol. 2010;37(5):1029-1034. doi: 10.3899/jrheum.091120Altobelli E, Angeletti PM, Petrocelli R, Lapergola G, Farello G, Cannataro G, et al. Serum calprotectin a potential biomarker in juvenile idiopathic arthritis: A meta-analysis. J Clin Med. 2021;10(21):4861. doi: 10.3390/jcm10214861Altobelli E, Angeletti PM, Petrocelli R, Lapergola G, Farello G, Cannataro G, et al. Serum calprotectin a potential biomarker in juvenile idiopathic arthritis: A meta-analysis. J Clin Med. 2021;10(21):4861. doi: 10.3390/jcm10214861Pardeo M, Vastert SJ, De Benedetti F. It is about time: The first validated biomarker for early diagnosis of systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2022;61(7):2724-2725. doi: 10.1093/rheumatology/keab948Pardeo M, Vastert SJ, De Benedetti F. It is about time: The first validated biomarker for early diagnosis of systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2022;61(7):2724-2725. doi: 10.1093/rheumatology/keab948Fautrel B, Mitrovic S, De Matteis A, Bindoli S, Antón J, Belot A, et al. EULAR/PReS recommendations for the diagnosis and management of Still’s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still’s disease. Ann Rheum Dis. 2024;83(12):1614-1627. doi: 10.1136/ard-2024-225851Fautrel B, Mitrovic S, De Matteis A, Bindoli S, Antón J, Belot A, et al. EULAR/PReS recommendations for the diagnosis and management of Still’s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still’s disease. Ann Rheum Dis. 2024;83(12):1614-1627. doi: 10.1136/ard-2024-225851Hinze CH, Foell D, Kessel C. Treatment of systemic juvenile idiopathic arthritis. Nat Rev Rheumatol. 2023;19(12):778-789. doi: 10.1038/s41584-023-01042-zHinze CH, Foell D, Kessel C. Treatment of systemic juvenile idiopathic arthritis. Nat Rev Rheumatol. 2023;19(12):778-789. doi: 10.1038/s41584-023-01042-zShen Y, Jia J, Teng J, Yang C, Hu Q. Advancing personalised precision treatment for Still’s disease based on molecular characteristics and disease progression. Lancet Rheumatol. 2025;7(2):e127-e140. doi: 10.1016/S2665-9913(24)00225-X.Shen Y, Jia J, Teng J, Yang C, Hu Q. Advancing personalised precision treatment for Still’s disease based on molecular characteristics and disease progression. Lancet Rheumatol. 2025;7(2):e127-e140. doi: 10.1016/S2665-9913(24)00225-X.Oktayoglu P, Bozkurt M, Mete N, Caglayan M, Em S, Nas K. Elevated serum levels of calprotectin (myeloid-related protein 8/14) in patients with ankylosing spondylitis and its association with disease activity and quality of life. J Investig Med. 2014;62(6):880-884. doi: 10.1097/JIM.0000000000000095Oktayoglu P, Bozkurt M, Mete N, Caglayan M, Em S, Nas K. Elevated serum levels of calprotectin (myeloid-related protein 8/14) in patients with ankylosing spondylitis and its association with disease activity and quality of life. J Investig Med. 2014;62(6):880-884. doi: 10.1097/JIM.0000000000000095Hu H, Du F, Zhang S, Zhang W. Serum calprotectin correlates with risk and disease severity of ankylosing spondylitis and its change during first month might predict favorable response to treatment. Mod Rheumatol. 2019;29(5):836-842. doi: 10.1080/14397595.2018.1519103Hu H, Du F, Zhang S, Zhang W. Serum calprotectin correlates with risk and disease severity of ankylosing spondylitis and its change during first month might predict favorable response to treatment. Mod Rheumatol. 2019;29(5):836-842. doi: 10.1080/14397595.2018.1519103Gupta L, Bhattacharya S, Agarwal V, Aggarwal A. Elevated levels of serum MRP8/14 in ankylosing spondylitis: Associated with peripheral arthritis and active disease. Clin Rheumatol. 2016;35(12):3075-3079. doi: 10.1007/s10067-016-3448-xGupta L, Bhattacharya S, Agarwal V, Aggarwal A. Elevated levels of serum MRP8/14 in ankylosing spondylitis: Associated with peripheral arthritis and active disease. Clin Rheumatol. 2016;35(12):3075-3079. doi: 10.1007/s10067-016-3448-xTurina MC, Yeremenko N, Paramarta JE, De Rycke L, Baeten D. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther. 2014;16(4):413. doi: 10.1186/s13075-014-0413-4Turina MC, Yeremenko N, Paramarta JE, De Rycke L, Baeten D. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther. 2014;16(4):413. doi: 10.1186/s13075-014-0413-4Rademacher J, Tietz LM, Le L, Hartl A, Hermann KA, Sieper J, et al. Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis. Rheumatology (Oxford). 2019;58(9):1556-1564. doi: 10.1093/rheumatology/kez025Rademacher J, Tietz LM, Le L, Hartl A, Hermann KA, Sieper J, et al. Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis. Rheumatology (Oxford). 2019;58(9):1556-1564. doi: 10.1093/rheumatology/kez025Jarlborg M, Courvoisier DS, Lamacchia C, Martinez Prat L, Mahler M, Bentow C, et al.; physicians of the Swiss Clinical Quality Management (SCQM) registry. Serum calprotectin: A promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res Ther. 2020;22(1):105. doi: 10.1186/s13075-020-02190-3Jarlborg M, Courvoisier DS, Lamacchia C, Martinez Prat L, Mahler M, Bentow C, et al.; physicians of the Swiss Clinical Quality Management (SCQM) registry. Serum calprotectin: A promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res Ther. 2020;22(1):105. doi: 10.1186/s13075-020-02190-3Levitova A, Hulejova H, Spiritovic M, Pavelka K, Senolt L, Husakova M. Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Arthritis Res Ther. 2016;18(1):275. doi: 10.1186/s13075-016-1180-1Levitova A, Hulejova H, Spiritovic M, Pavelka K, Senolt L, Husakova M. Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Arthritis Res Ther. 2016;18(1):275. doi: 10.1186/s13075-016-1180-1Ma Y, Fan D, Xu S, Deng J, Gao X, Guan S, et al. Calprotectin in spondyloarthritis: A systematic review and meta-analysis. Int Immunopharmacol. 2020;88:106948. doi: 10.1016/j.intimp.2020.106948Ma Y, Fan D, Xu S, Deng J, Gao X, Guan S, et al. Calprotectin in spondyloarthritis: A systematic review and meta-analysis. Int Immunopharmacol. 2020;88:106948. doi: 10.1016/j.intimp.2020.106948Hammer HB, Kvien TK, Glennås A, Melby K. A longitudinal study of calprotectin as an inflammatory marker in patients with reactive arthritis. Clin Exp Rheumatol. 1995;13(1):59-64.Hammer HB, Kvien TK, Glennås A, Melby K. A longitudinal study of calprotectin as an inflammatory marker in patients with reactive arthritis. Clin Exp Rheumatol. 1995;13(1):59-64.Sokolova MV, Simon D, Nas K, Zaiss MM, Luo Y, Zhao Y, et al. A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations. Arthritis Res Ther. 2020;22(1):26. doi: 10.1186/s13075-020-2111-8Sokolova MV, Simon D, Nas K, Zaiss MM, Luo Y, Zhao Y, et al. A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations. Arthritis Res Ther. 2020;22(1):26. doi: 10.1186/s13075-020-2111-8Hansson C, Eriksson C, Alenius GM. S-calprotectin (S100A8/ S100A9): A potential marker of inflammation in patients with psoriatic arthritis. J Immunol Res. 2014;2014:696415. doi: 10.1155/2014/696415Hansson C, Eriksson C, Alenius GM. S-calprotectin (S100A8/ S100A9): A potential marker of inflammation in patients with psoriatic arthritis. J Immunol Res. 2014;2014:696415. doi: 10.1155/2014/696415Li B, Li G, Song Z, Zhang Z. Serum calprotectin as a promising inflammatory biomarker in psoriatic arthritis: A 1-year longitudinal study. Rheumatol Ther. 2023;10(1):149-160. doi: 10.1007/s40744-022-00501-5Li B, Li G, Song Z, Zhang Z. Serum calprotectin as a promising inflammatory biomarker in psoriatic arthritis: A 1-year longitudinal study. Rheumatol Ther. 2023;10(1):149-160. doi: 10.1007/s40744-022-00501-5Aguilar-Zamora M, Montolio-Chiva L, Morena IDL, Lopez JM, Feced Olmos C, Orenes Vera AV, et al. Calprotectin in serum and synovial fluid as a biomarker in acute arthritis. Ann Rheum Dis. 2019;78:2021. doi: 10.1136/annrheumdis-2019-eular.7581Aguilar-Zamora M, Montolio-Chiva L, Morena IDL, Lopez JM, Feced Olmos C, Orenes Vera AV, et al. Calprotectin in serum and synovial fluid as a biomarker in acute arthritis. Ann Rheum Dis. 2019;78:2021. doi: 10.1136/annrheumdis-2019-eular.7581Cheng IT, Meng H, Li M, Li EK, Wong PC, Lee J, et al. Serum calprotectin level is independently associated with carotid plaque presence in patients with psoriatic arthritis. Front Med (Lausanne). 2022;9:932696. doi: 10.3389/fmed.2022.932696Cheng IT, Meng H, Li M, Li EK, Wong PC, Lee J, et al. Serum calprotectin level is independently associated with carotid plaque presence in patients with psoriatic arthritis. Front Med (Lausanne). 2022;9:932696. doi: 10.3389/fmed.2022.932696Pepper RJ, Hamour S, Chavele KM, Todd SK, Rasmussen N, Flint S, et al. Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis. Kidney Int. 2013;83(6):1150-1158. doi: 10.1038/ki.2013.2Pepper RJ, Hamour S, Chavele KM, Todd SK, Rasmussen N, Flint S, et al. Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis. Kidney Int. 2013;83(6):1150-1158. doi: 10.1038/ki.2013.2Pepper RJ, Draibe JB, Caplin B, Fervenza FC, Hoffman GS, Kallenberg CG, et al.; RAVE-Immune Tolerance Network Research Group. Association of serum calprotectin (S100A8/A9) level with disease relapse in proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2017;69(1):185-193. doi: 10.1002/art.39814Pepper RJ, Draibe JB, Caplin B, Fervenza FC, Hoffman GS, Kallenberg CG, et al.; RAVE-Immune Tolerance Network Research Group. Association of serum calprotectin (S100A8/A9) level with disease relapse in proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2017;69(1):185-193. doi: 10.1002/art.39814Martinez Valenzuela L, Draibe J, Quero Ramos M, Fulladosa Oliveras X, Melilli E, Cruzado Garrit JM, et al. Calprotectin as a smoldering activity detection tool and renal prognosis biomarker in ANCA associated vasculitis. PLoS One. 2018;13(10):e0205982. doi: 10.1371/journal.pone.0205982Martinez Valenzuela L, Draibe J, Quero Ramos M, Fulladosa Oliveras X, Melilli E, Cruzado Garrit JM, et al. Calprotectin as a smoldering activity detection tool and renal prognosis biomarker in ANCA associated vasculitis. PLoS One. 2018;13(10):e0205982. doi: 10.1371/journal.pone.0205982Bai X, Xu PC, Chen T, Zhang HM, Wu SJ, Yang X, et al. The potential pathogenic roles of S100A8/ A9 and S100A12 in patients with MPO-ANCA-positive vasculitis. BMC Immunol. 2022;23(1):42. doi: 10.1186/s12865-022-00513-4Bai X, Xu PC, Chen T, Zhang HM, Wu SJ, Yang X, et al. The potential pathogenic roles of S100A8/ A9 and S100A12 in patients with MPO-ANCA-positive vasculitis. BMC Immunol. 2022;23(1):42. doi: 10.1186/s12865-022-00513-4Romand X, Paclet MH, Chuong MV, Gaudin P, Pagnoux C, Guillevin L, et al. Serum calprotectin and renal function decline in ANCA-associated vasculitides: A post hoc analysis of MAINRITSAN trial. RMD Open. 2023;9(4):e003477. doi: 10.1136/rmdopen-2023-003477Romand X, Paclet MH, Chuong MV, Gaudin P, Pagnoux C, Guillevin L, et al. Serum calprotectin and renal function decline in ANCA-associated vasculitides: A post hoc analysis of MAINRITSAN trial. RMD Open. 2023;9(4):e003477. doi: 10.1136/rmdopen-2023-003477Brown KL, Lubieniecka JM, Armaroli G, Kessel K, Gibson KM, Graham J, et al. S100A12 serum levels and PMN counts are elevated in childhood systemic vasculitides especially involving proteinase 3 specific anti-neutrophil cytoplasmic antibodies. Front Pediatr. 2018;6:341. doi: 10.3389/fped.2018.00341Brown KL, Lubieniecka JM, Armaroli G, Kessel K, Gibson KM, Graham J, et al. S100A12 serum levels and PMN counts are elevated in childhood systemic vasculitides especially involving proteinase 3 specific anti-neutrophil cytoplasmic antibodies. Front Pediatr. 2018;6:341. doi: 10.3389/fped.2018.00341Srsen S, Held M, Sestan M, Kifer N, Kozmar A, Supe Domic D, et al. Serum levels of S100A8/A9 as a biomarker of disease activity in patients with IgA vasculitis. Biomedicines. 2024;12(4):750. doi: 10.3390/biomedicines12040750Srsen S, Held M, Sestan M, Kifer N, Kozmar A, Supe Domic D, et al. Serum levels of S100A8/A9 as a biomarker of disease activity in patients with IgA vasculitis. Biomedicines. 2024;12(4):750. doi: 10.3390/biomedicines12040750Zandstra J, van de Geer A, Tanck MWT, van Stijn-Bringas Dimitriades D, Aarts CEM, et al.; EUCLIDS Consortium, PERFORM Consortium and UK Kawasaki Disease Genetics Study Network. Biomarkers for the discrimination of acute Kawasaki disease from infections in childhood. Front Pediatr. 2020;8:355. doi: 10.3389/fped.2020.00355Zandstra J, van de Geer A, Tanck MWT, van Stijn-Bringas Dimitriades D, Aarts CEM, et al.; EUCLIDS Consortium, PERFORM Consortium and UK Kawasaki Disease Genetics Study Network. Biomarkers for the discrimination of acute Kawasaki disease from infections in childhood. Front Pediatr. 2020;8:355. doi: 10.3389/fped.2020.00355Springer JM, Monach P, Cuthbertson D, Carette S, Khalidi NA, McAlear CA, et al. Serum S100 proteins as a marker of disease activity in large vessel vasculitis. J Clin Rheumatol. 2018;24(7):393-395. doi: 10.1097/RHU.0000000000000729Springer JM, Monach P, Cuthbertson D, Carette S, Khalidi NA, McAlear CA, et al. Serum S100 proteins as a marker of disease activity in large vessel vasculitis. J Clin Rheumatol. 2018;24(7):393-395. doi: 10.1097/RHU.0000000000000729Saut A, Paclet MH, Trocmé C, Toussaint B, Bocquet A, Bouillet L, et al. Serum calprotectin is a marker of disease activity in giant cell arteritis. Autoimmun Rev. 2023;22(12):103469. doi: 10.1016/j.autrev.2023.103469Saut A, Paclet MH, Trocmé C, Toussaint B, Bocquet A, Bouillet L, et al. Serum calprotectin is a marker of disease activity in giant cell arteritis. Autoimmun Rev. 2023;22(12):103469. doi: 10.1016/j.autrev.2023.103469Kmetova K, Chong E, Somanathapura KN, Sugur K, Kluge L, Yalavarthi S, et al. Calprotectin, a mechanistically informed biomarker for clinically isolated aortitis. Arthritis Rheumatol. 2024;76(Suppl 9). URL: https://acrabstracts.org/abstract/calprotectin-a-mechanistically-informed-biomarker-for-clinically-isolated-aortitis/ (Accessed: 16th June 2025).Kmetova K, Chong E, Somanathapura KN, Sugur K, Kluge L, Yalavarthi S, et al. Calprotectin, a mechanistically informed biomarker for clinically isolated aortitis. Arthritis Rheumatol. 2024;76(Suppl 9). URL: https://acrabstracts.org/abstract/calprotectin-a-mechanistically-informed-biomarker-for-clinically-isolated-aortitis/ (Accessed: 16th June 2025).Nordal HH, Brun JG, Halse AK, Madland TM, Fagerhol MK, Jonsson R. Calprotectin (S100A8/A9), S100A12, and EDTAresistant S100A12 complexes (ERAC) in primary Sjögren’s syndrome. Scand J Rheumatol. 2014;43(1):76-78. doi: 10.3109/03009742.2013.848930Nordal HH, Brun JG, Halse AK, Madland TM, Fagerhol MK, Jonsson R. Calprotectin (S100A8/A9), S100A12, and EDTAresistant S100A12 complexes (ERAC) in primary Sjögren’s syndrome. Scand J Rheumatol. 2014;43(1):76-78. doi: 10.3109/03009742.2013.848930Balarini GM, Zandonade E, Tanure L, Ferreira GA, Sardenberg WM, Serrano ÉV, et al. Serum calprotectin is a biomarker of carotid atherosclerosis in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol. 2016;34(6):1006-1012.Balarini GM, Zandonade E, Tanure L, Ferreira GA, Sardenberg WM, Serrano ÉV, et al. Serum calprotectin is a biomarker of carotid atherosclerosis in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol. 2016;34(6):1006-1012.Jazzar AA, Shirlaw PJ, Carpenter GH, Challacombe SJ, Proctor GB. Salivary S100A8/A9 in Sjögren’s syndrome accompanied by lymphoma. J Oral Pathol Med. 2018;47(9):900-906. doi: 10.1111/jop.12763Jazzar AA, Shirlaw PJ, Carpenter GH, Challacombe SJ, Proctor GB. Salivary S100A8/A9 in Sjögren’s syndrome accompanied by lymphoma. J Oral Pathol Med. 2018;47(9):900-906. doi: 10.1111/jop.12763Xu X, Wu WY, Tu WZ, Chu HY, Zhu XX, Liang MR, et al. Increased expression of S100A8 and S100A9 in patients with diffuse cutaneous systemic sclerosis. A correlation with organ involvement and immunological abnormalities. Clin Rheumatol. 2013;32(10):1501-1510. doi: 10.1007/s10067-013-2305-4Xu X, Wu WY, Tu WZ, Chu HY, Zhu XX, Liang MR, et al. Increased expression of S100A8 and S100A9 in patients with diffuse cutaneous systemic sclerosis. A correlation with organ involvement and immunological abnormalities. Clin Rheumatol. 2013;32(10):1501-1510. doi: 10.1007/s10067-013-2305-4van Bon L, Cossu M, Loof A, Gohar F, Wittkowski H, Vonk M, et al. Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic sclerosis phenotype. Ann Rheum Dis. 2014;73(8):1585-1589. doi: 10.1136/annrheumdis-2013-205013van Bon L, Cossu M, Loof A, Gohar F, Wittkowski H, Vonk M, et al. Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic sclerosis phenotype. Ann Rheum Dis. 2014;73(8):1585-1589. doi: 10.1136/annrheumdis-2013-205013Ebrahimi B, Nazarinia M, Molayem M. Calprotectin, an available prognostic biomarker in systemic sclerosis: A systematic review. Clin Rheumatol. 2021;40(5):1709-1715. doi: 10.1007/s10067-020-05446-0Ebrahimi B, Nazarinia M, Molayem M. Calprotectin, an available prognostic biomarker in systemic sclerosis: A systematic review. Clin Rheumatol. 2021;40(5):1709-1715. doi: 10.1007/s10067-020-05446-0Pellicano C, Villa A, Carnazzo V, D’Ippolito G, Vinante I, Laterza F, et al. Serum calprotectin as a novel biomarker of disease severity and activity in systemic sclerosis patients. Int J Mol Sci. 2025;26(9):4290. doi: 10.3390/ijms26094290Pellicano C, Villa A, Carnazzo V, D’Ippolito G, Vinante I, Laterza F, et al. Serum calprotectin as a novel biomarker of disease severity and activity in systemic sclerosis patients. Int J Mol Sci. 2025;26(9):4290. doi: 10.3390/ijms26094290Nistala K, Varsani H, Wittkowski H, Vogl T, Krol P, Shah V, et al. Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositis. Arthritis Res Ther. 2013;15(5):R131. doi: 10.1186/ar4311Nistala K, Varsani H, Wittkowski H, Vogl T, Krol P, Shah V, et al. Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositis. Arthritis Res Ther. 2013;15(5):R131. doi: 10.1186/ar4311Lou Y, Zheng Y, Fan B, Zhang L, Zhu F, Wang X, et al. Serum levels of interleukins and S100A8/A9 correlate with clinical severity in patients with dermatomyositis-associated interstitial lung disease. BMC Pulm Med. 2020;20(1):196. doi: 10.1186/s12890-020-01226-3Lou Y, Zheng Y, Fan B, Zhang L, Zhu F, Wang X, et al. Serum levels of interleukins and S100A8/A9 correlate with clinical severity in patients with dermatomyositis-associated interstitial lung disease. BMC Pulm Med. 2020;20(1):196. doi: 10.1186/s12890-020-01226-3Soyfoo MS, Roth J, Vogl T, Pochet R, Decaux G. Phagocytespecific S100A8/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus. J Rheumatol. 2009;36(10):2190-2194.Soyfoo MS, Roth J, Vogl T, Pochet R, Decaux G. Phagocytespecific S100A8/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus. J Rheumatol. 2009;36(10):2190-2194.Tydén H, Lood C, Gullstrand B, Jönsen A, Nived O, Sturfelt G, et al. Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. Rheumatology (Oxford). 2013;52(11):2048-2055. doi: 10.1093/rheumatology/ket263Tydén H, Lood C, Gullstrand B, Jönsen A, Nived O, Sturfelt G, et al. Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. Rheumatology (Oxford). 2013;52(11):2048-2055. doi: 10.1093/rheumatology/ket263Haga HJ, Brun JG, Berntzen HB, Cervera R, Khamashta M, Hughes GR. Calprotectin in patients with systemic lupus erythematosus: Relation to clinical and laboratory parameters of disease activity. Lupus. 1993;2(1):47-50. doi: 10.1177/096120339300200108Haga HJ, Brun JG, Berntzen HB, Cervera R, Khamashta M, Hughes GR. Calprotectin in patients with systemic lupus erythematosus: Relation to clinical and laboratory parameters of disease activity. Lupus. 1993;2(1):47-50. doi: 10.1177/096120339300200108Tydén H, Lood C, Gullstrand B, Jönsen A, Ivars F, Leanderson T, et al. Pro-inflammatory S100 proteins are associated with glomerulonephritis and anti-dsDNA antibodies in systemic lupus erythematosus. Lupus. 2017;26(2):139-149. doi: 10.1177/0961203316655208Tydén H, Lood C, Gullstrand B, Jönsen A, Ivars F, Leanderson T, et al. Pro-inflammatory S100 proteins are associated with glomerulonephritis and anti-dsDNA antibodies in systemic lupus erythematosus. Lupus. 2017;26(2):139-149. doi: 10.1177/0961203316655208Sumova B, Cerezo LA, Szczukova L, Nekvindova L, Uher M, Hulejova H, et al. Circulating S100 proteins effectively discriminate SLE patients from healthy controls: A cross-sectional study. Rheumatol Int. 2019;39(3):469-478. doi: 10.1007/s00296-018-4190-2Sumova B, Cerezo LA, Szczukova L, Nekvindova L, Uher M, Hulejova H, et al. Circulating S100 proteins effectively discriminate SLE patients from healthy controls: A cross-sectional study. Rheumatol Int. 2019;39(3):469-478. doi: 10.1007/s00296-018-4190-2Wakiya R, Kameda T, Ueeda K, Nakashima S, Shimada H, Mansour MF, et al. Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus. Lupus. 2019;28(7):826-833. doi: 10.1177/0961203319846391Wakiya R, Kameda T, Ueeda K, Nakashima S, Shimada H, Mansour MF, et al. Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus. Lupus. 2019;28(7):826-833. doi: 10.1177/0961203319846391Donohue SJ, Midgley A, Davies JC, Wright RD, Bruce I, Beresford MW, et al.; MRC MASTERPLANS Consortium; UK jSLE Cohort Study and Repository. Differential analysis of serum and urine S100 proteins in juvenile-onset systemic lupus erythematosus (jSLE). Clin Immunol. 2020;214:108375. doi: 10.1016/j.clim.2020.108375Donohue SJ, Midgley A, Davies JC, Wright RD, Bruce I, Beresford MW, et al.; MRC MASTERPLANS Consortium; UK jSLE Cohort Study and Repository. Differential analysis of serum and urine S100 proteins in juvenile-onset systemic lupus erythematosus (jSLE). Clin Immunol. 2020;214:108375. doi: 10.1016/j.clim.2020.108375Davies JC, Midgley A, Carlsson E, Donohue S, Bruce IN, Beresford MW, et al. Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment. RMD Open. 2020;6(2):e001257. doi: 10.1136/rmdopen-2020-001257Davies JC, Midgley A, Carlsson E, Donohue S, Bruce IN, Beresford MW, et al. Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment. RMD Open. 2020;6(2):e001257. doi: 10.1136/rmdopen-2020-001257Kim JW, Jung JY, Lee SW, Baek WY, Kim HA, Suh CH. S100A8 in serum, urine, and saliva as a potential biomarker for systemic lupus erythematosus. Front Immunol. 2022;13:886209. doi: 10.3389/fimmu.2022.886209Kim JW, Jung JY, Lee SW, Baek WY, Kim HA, Suh CH. S100A8 in serum, urine, and saliva as a potential biomarker for systemic lupus erythematosus. Front Immunol. 2022;13:886209. doi: 10.3389/fimmu.2022.886209Homa-Mlak I, Mazurek M, Majdan A, Mlak R, Majdan M, Mełecka-Massalska T. Serum calprotectin – a NET product – as a biomarker of disease activity in patients with systemic lupus erythematosus: A single-center case-control study from Poland. Med Sci Monit. 2022;28:e936534. doi: 10.12659/MSM.936534Homa-Mlak I, Mazurek M, Majdan A, Mlak R, Majdan M, Mełecka-Massalska T. Serum calprotectin – a NET product – as a biomarker of disease activity in patients with systemic lupus erythematosus: A single-center case-control study from Poland. Med Sci Monit. 2022;28:e936534. doi: 10.12659/MSM.936534Zervides KA, Jern A, Nystedt J, Gullstrand B, Nilsson PC, Sundgren PC, et al. Serum S100A8/A9 concentrations are associated with neuropsychiatric involvement in systemic lupus erythematosus: A cross-sectional study. BMC Rheumatol. 2022;6(1):38. doi: 10.1186/s41927-022-00268-wZervides KA, Jern A, Nystedt J, Gullstrand B, Nilsson PC, Sundgren PC, et al. Serum S100A8/A9 concentrations are associated with neuropsychiatric involvement in systemic lupus erythematosus: A cross-sectional study. BMC Rheumatol. 2022;6(1):38. doi: 10.1186/s41927-022-00268-wMuñoz-Grajales C, Barraclough ML, Diaz-Martinez JP, Su J, Bingham K, Kakvan M, et al, Serum S100A8/ A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment. Front Immunol. 2024;14:1326751. doi: 10.3389/fimmu.2023.1326751Muñoz-Grajales C, Barraclough ML, Diaz-Martinez JP, Su J, Bingham K, Kakvan M, et al, Serum S100A8/ A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment. Front Immunol. 2024;14:1326751. doi: 10.3389/fimmu.2023.1326751Muñoz-Grajales C, Barraclough ML, Diaz-Martinez JP, Su J, Bingham K, Kakvan M, et al. Association of elevated serum S100A8/A9 levels and cognitive impairment in systemic lupus erythematosus patients. Arthritis Care Res (Hoboken). 2025 May 19. doi: 10.1002/acr.25575Muñoz-Grajales C, Barraclough ML, Diaz-Martinez JP, Su J, Bingham K, Kakvan M, et al. Association of elevated serum S100A8/A9 levels and cognitive impairment in systemic lupus erythematosus patients. Arthritis Care Res (Hoboken). 2025 May 19. doi: 10.1002/acr.25575Kitagori K, Oku T, Wakabayashi M, Nakajima T, Nakashima R, Tian X, et al. Expression of S100A8 protein on B cells is associated with disease activity in patients with systemic lupus erythematosus. Arthritis Res Ther. 2023;25(1):76. doi: 10.1186/s13075-023-03057-zKitagori K, Oku T, Wakabayashi M, Nakajima T, Nakashima R, Tian X, et al. Expression of S100A8 protein on B cells is associated with disease activity in patients with systemic lupus erythematosus. Arthritis Res Ther. 2023;25(1):76. doi: 10.1186/s13075-023-03057-zZhao Y, Qi W, Huang C, Zhou Y, Wang Q, Tian X, et al. Serum calprotectin as a potential predictor of microvascular manifestations in patients with antiphospholipid syndrome. Rheumatol Ther. 2023;10(6):1769-1783. doi: 10.1007/s40744-023-00610-9Zhao Y, Qi W, Huang C, Zhou Y, Wang Q, Tian X, et al. Serum calprotectin as a potential predictor of microvascular manifestations in patients with antiphospholipid syndrome. Rheumatol Ther. 2023;10(6):1769-1783. doi: 10.1007/s40744-023-00610-9Hoy CK, Naveen Kumar SK, Navaz SA, Sugur K, Yalavarthi S, Sarosh C, et al. Calprotectin impairs platelet survival in patients with primary antiphospholipid syndrome. Arthritis Rheumatol. 2024;76(6):928-935. doi: 10.1002/art.42801Hoy CK, Naveen Kumar SK, Navaz SA, Sugur K, Yalavarthi S, Sarosh C, et al. Calprotectin impairs platelet survival in patients with primary antiphospholipid syndrome. Arthritis Rheumatol. 2024;76(6):928-935. doi: 10.1002/art.42801Sloan EE, Kmetova K, Naveen Kumar SK, Kluge L, Chong E, Hoy CK, et al. Non-criteria antiphospholipid antibodies and calprotectin as potential biomarkers in pediatric antiphospholipid syndrome. Clin Immunol. 2024;261:109926. doi: 10.1016/j.clim.2024.109926Sloan EE, Kmetova K, Naveen Kumar SK, Kluge L, Chong E, Hoy CK, et al. Non-criteria antiphospholipid antibodies and calprotectin as potential biomarkers in pediatric antiphospholipid syndrome. Clin Immunol. 2024;261:109926. doi: 10.1016/j.clim.2024.109926Oktayoglu P, Mete N, Caglayan M, Bozkurt M, Bozan T, Em S, et al. Elevated serum levels of calprotectin (MRP8/MRP14) in patients with Behçet’s disease and its association with disease activity and quality of life. Scand J Clin Lab Invest. 2015;75(2):106-112. doi: 10.3109/00365513.2014.984319Oktayoglu P, Mete N, Caglayan M, Bozkurt M, Bozan T, Em S, et al. Elevated serum levels of calprotectin (MRP8/MRP14) in patients with Behçet’s disease and its association with disease activity and quality of life. Scand J Clin Lab Invest. 2015;75(2):106-112. doi: 10.3109/00365513.2014.984319Omma A, Sandikci SC, Colak S, Tecer D, Yucel C, Ozbalkan Z. Serum calprotectin and ischemia modified albumin levels as markers of disease activity in Behçet’s disease. Postepy Dermatol Alergol. 2018;35(6):609-613. doi: 10.5114/pdia.2017.71269Omma A, Sandikci SC, Colak S, Tecer D, Yucel C, Ozbalkan Z. Serum calprotectin and ischemia modified albumin levels as markers of disease activity in Behçet’s disease. Postepy Dermatol Alergol. 2018;35(6):609-613. doi: 10.5114/pdia.2017.71269Tezcan D, Onmaz DE, Sivrikaya A, Hakbilen S, Körez MK, Gülcemal S, et al. Assessment of serum neopterin and calprotectin as biomarkers for subclinical inflammation in patients with familial Mediterranean fever. Ir J Med Sci. 2023;192(4):2015-2022. doi: 10.1007/s11845-022-03173-wTezcan D, Onmaz DE, Sivrikaya A, Hakbilen S, Körez MK, Gülcemal S, et al. Assessment of serum neopterin and calprotectin as biomarkers for subclinical inflammation in patients with familial Mediterranean fever. Ir J Med Sci. 2023;192(4):2015-2022. doi: 10.1007/s11845-022-03173-wKilinc OC, Akdeniz YS, Taskin Z, Karabulut M, Kaya A, Bolayırlı IM, et al. Exploring S100A8/A9, neopterin, and MMP3 in familial Mediterranean fever. Clin Exp Immunol. 2024;218(1):93-100. doi: 10.1093/cei/uxae049Kilinc OC, Akdeniz YS, Taskin Z, Karabulut M, Kaya A, Bolayırlı IM, et al. Exploring S100A8/A9, neopterin, and MMP3 in familial Mediterranean fever. Clin Exp Immunol. 2024;218(1):93-100. doi: 10.1093/cei/uxae049Polat MG, Omma A, Gokcen N, Kilinckaya MF, Ozkan Karaahmetoglu S. Role of serum calprotectin in identifying familial Mediterranean fever attacks. Ir J Med Sci. 2024;193(4):1901- 1909. doi: 10.1007/s11845-024-03659-9Polat MG, Omma A, Gokcen N, Kilinckaya MF, Ozkan Karaahmetoglu S. Role of serum calprotectin in identifying familial Mediterranean fever attacks. Ir J Med Sci. 2024;193(4):1901- 1909. doi: 10.1007/s11845-024-03659-9Asan G, Derin ME, Doğan HO, Bayram M, Şahin M, Şahin A. Can calprotectin show subclinical inflammation in familial Mediterranean fever patients? J Korean Med Sci. 2020;35(10):e63. doi: 10.3346/jkms.2020.35.e63Asan G, Derin ME, Doğan HO, Bayram M, Şahin M, Şahin A. Can calprotectin show subclinical inflammation in familial Mediterranean fever patients? J Korean Med Sci. 2020;35(10):e63. doi: 10.3346/jkms.2020.35.e63Holzinger D, Nippe N, Vogl T, Marketon K, Mysore V, Weinhage T, et al. Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in gout. Arthritis Rheumatol. 2014;66(5):1327-1339. doi: 10.1002/art.38369Holzinger D, Nippe N, Vogl T, Marketon K, Mysore V, Weinhage T, et al. Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in gout. Arthritis Rheumatol. 2014;66(5):1327-1339. doi: 10.1002/art.38369Vedder D, Gerritsen M, Nurmohamed MT, van Vollenhoven RF, Lood C. A neutrophil signature is strongly associated with increased cardiovascular risk in gout. Rheumatology (Oxford). 2021;60(6):2783-2790. doi: 10.1093/rheumatology/keaa712Vedder D, Gerritsen M, Nurmohamed MT, van Vollenhoven RF, Lood C. A neutrophil signature is strongly associated with increased cardiovascular risk in gout. Rheumatology (Oxford). 2021;60(6):2783-2790. doi: 10.1093/rheumatology/keaa712Safa A, Bagherifard A, Hadi Al-Baseesee H, Amini Kadijani A, Yahyazadeh H, et al. Serum calprotectin as a blood-based biomarker for monitoring knee osteoarthritis at early but not late stages. Cartilage. 2021;13(Suppl 1):1566S-1571S. doi: 10.1177/1947603520961161Safa A, Bagherifard A, Hadi Al-Baseesee H, Amini Kadijani A, Yahyazadeh H, et al. Serum calprotectin as a blood-based biomarker for monitoring knee osteoarthritis at early but not late stages. Cartilage. 2021;13(Suppl 1):1566S-1571S. doi: 10.1177/1947603520961161Frade-Sosa B, Chacur CA, Augé JM, Ponce A, Sarmiento-Monroy JC, Azuaga AB, et al. Calprotectin in patients with rheumatic immunomediated adverse effects induced by checkpoints inhibitors. Cancers (Basel). 2023;15(11):2984. doi: 10.3390/cancers15112984Frade-Sosa B, Chacur CA, Augé JM, Ponce A, Sarmiento-Monroy JC, Azuaga AB, et al. Calprotectin in patients with rheumatic immunomediated adverse effects induced by checkpoints inhibitors. Cancers (Basel). 2023;15(11):2984. doi: 10.3390/cancers15112984Kaya T, Yaylacı S, Nalbant A, Yıldırım İ, Kocayiğit H, Çokluk E, et al. Serum calprotectin as a novel biomarker for severity of COVID-19 disease. Ir J Med Sci. 2022;191(1):59-64. doi: 10.1007/s11845-021-02565-8Kaya T, Yaylacı S, Nalbant A, Yıldırım İ, Kocayiğit H, Çokluk E, et al. Serum calprotectin as a novel biomarker for severity of COVID-19 disease. Ir J Med Sci. 2022;191(1):59-64. doi: 10.1007/s11845-021-02565-8Mahler M, Meroni PL, Infantino M, Buhler KA, Fritzler MJ. Circulating calprotectin as a biomarker of COVID-19 severity. Expert Rev Clin Immunol. 2021;17(5):431-443. doi: 10.1080/1744666X.2021.1905526Mahler M, Meroni PL, Infantino M, Buhler KA, Fritzler MJ. Circulating calprotectin as a biomarker of COVID-19 severity. Expert Rev Clin Immunol. 2021;17(5):431-443. doi: 10.1080/1744666X.2021.1905526Zhang H, Zhang Q, Liu K, Yuan Z, Xu X, Dong J. Elevated level of circulating calprotectin correlates with severity and high mortality in patients with COVID-19. Immun Inflamm Dis. 2024;12(3):e1212. doi: 10.1002/iid3.1212Zhang H, Zhang Q, Liu K, Yuan Z, Xu X, Dong J. Elevated level of circulating calprotectin correlates with severity and high mortality in patients with COVID-19. Immun Inflamm Dis. 2024;12(3):e1212. doi: 10.1002/iid3.1212Udeh R, Advani S, de Guadiana Romualdo LG, Dolja-Gore X. Calprotectin, an emerging biomarker of interest in COVID-19: A systematic review and meta-analysis. J Clin Med. 2021;10(4):775. doi: 10.3390/jcm10040775Udeh R, Advani S, de Guadiana Romualdo LG, Dolja-Gore X. Calprotectin, an emerging biomarker of interest in COVID-19: A systematic review and meta-analysis. J Clin Med. 2021;10(4):775. doi: 10.3390/jcm10040775Machahua C, Guler SA, Horn MP, Planas-Cerezales L, Montes-Worboys A, Geiser TK, et al. Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: A crosssectional study in two independent cohorts. BMJ Open Respir Res. 2021;8(1):e000827. doi: 10.1136/bmjresp-2020-000827Machahua C, Guler SA, Horn MP, Planas-Cerezales L, MontesWorboys A, Geiser TK, et al. Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: A crosssectional study in two independent cohorts. BMJ Open Respir Res. 2021;8(1):e000827. doi: 10.1136/bmjresp-2020-000827Kotsiou OS, Papagiannis D, Papadopoulou R, Gourgoulianis KI. Calprotectin in lung diseases. Int J Mol Sci. 2021;22(4):1706. doi: 10.3390/ijms22041706Kotsiou OS, Papagiannis D, Papadopoulou R, Gourgoulianis KI. Calprotectin in lung diseases. Int J Mol Sci. 2021;22(4):1706. doi: 10.3390/ijms22041706Zuo Y, Naveen Kumar SK, Navaz S, Liang W, Sugur K, Kmetova K, et al. Epidemiological and translational study of calprotectin and atherosclerotic cardiovascular disease. JAMA Cardiol. 2025;10(7):718-727. doi: 10.1001/jamacardio.2025.0945Zuo Y, Naveen Kumar SK, Navaz S, Liang W, Sugur K, Kmetova K, et al. Epidemiological and translational study of calprotectin and atherosclerotic cardiovascular disease. JAMA Cardiol. 2025;10(7):718-727. doi: 10.1001/jamacardio.2025.0945Saenz-Pipaon G, Ravassa S, Larsen KL, Martinez-Aguilar E, Orbe J, Rodriguez JA, et al. Lipocalin-2 and calprotectin potential prognosis biomarkers in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2022;63(4):648-656. doi: 10.1016/j.ejvs.2022.01.012Saenz-Pipaon G, Ravassa S, Larsen KL, Martinez-Aguilar E, Orbe J, Rodriguez JA, et al. Lipocalin-2 and calprotectin potential prognosis biomarkers in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2022;63(4):648-656. doi: 10.1016/j.ejvs.2022.01.012Chen F, He Z, Wang C, Si J, Chen Z, Guo Y. Advances in the study of S100A9 in cardiovascular diseases. Cell Prolif. 2024;57(8):e13636. doi: 10.1111/cpr.13636Chen F, He Z, Wang C, Si J, Chen Z, Guo Y. Advances in the study of S100A9 in cardiovascular diseases. Cell Prolif. 2024;57(8):e13636. doi: 10.1111/cpr.13636Plana E, Oto J, Herranz R, Medina P, Cana F, Miralles M. Calprotectin as a new inflammatory marker of abdominal aortic aneurysm: A pilot study. Vasc Med. 202;29(2):189-199. doi: 10.1177/1358863X241231494Plana E, Oto J, Herranz R, Medina P, Cana F, Miralles M. Calprotectin as a new inflammatory marker of abdominal aortic aneurysm: A pilot study. Vasc Med. 202;29(2):189-199. doi: 10.1177/1358863X241231494Haybar H, Ramezani B, Assareh AR, Kardooni A, Azizidoost S. Calprotectin correlates with reduced level of LVEF and occurrence of cardiac arrhythmia in STEMI patients. Adv Biomed Res. 2024;13:90. doi: 10.4103/abr.abr_438_23Haybar H, Ramezani B, Assareh AR, Kardooni A, Azizidoost S. Calprotectin correlates with reduced level of LVEF and occurrence of cardiac arrhythmia in STEMI patients. Adv Biomed Res. 2024;13:90. doi: 10.4103/abr.abr_438_23Amaya-Garrido A, Brunet M, Buffin-Meyer B, Piedrafita A, Grzesiak L, Agbegbo E, et al. Calprotectin is a contributor to and potential therapeutic target for vascular calcification in chronic kidney disease. Sci Transl Med. 2023;15(712):eabn5939. doi: 10.1126/scitranslmed.abn5939Amaya-Garrido A, Brunet M, Buffin-Meyer B, Piedrafita A, Grzesiak L, Agbegbo E, et al. Calprotectin is a contributor to and potential therapeutic target for vascular calcification in chronic kidney disease. Sci Transl Med. 2023;15(712):eabn5939. doi: 10.1126/scitranslmed.abn5939Reshadmanesh T, Behnoush AH, Farajollahi M, Khalaji A, Ghondaghsaz E, Ahangar H. Circulating levels of calprotectin as a biomarker in patients with coronary artery disease: A systematic review and meta-analysis. Clin Cardiol. 2024;47(7):e24315. doi: 10.1002/clc.24315Reshadmanesh T, Behnoush AH, Farajollahi M, Khalaji A, Ghondaghsaz E, Ahangar H. Circulating levels of calprotectin as a biomarker in patients with coronary artery disease: A systematic review and meta-analysis. Clin Cardiol. 2024;47(7):e24315. doi: 10.1002/clc.24315Porsch F, Binder CJ. Autoimmune diseases and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2024;21(11):780-807. doi: 10.1038/s41569-024-01045-7Porsch F, Binder CJ. Autoimmune diseases and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2024;21(11):780-807. doi: 10.1038/s41569-024-01045-7Sparks R, Rachmaninoff N, Lau WW, Hirsch DC, Bansal N, Martins AJ, et al. A unified metric of human immune health. Nat Med. 2024;30(9):2461-2472. doi: 10.1038/s41591-024-03092-6Sparks R, Rachmaninoff N, Lau WW, Hirsch DC, Bansal N, Martins AJ, et al. A unified metric of human immune health. Nat Med. 2024;30(9):2461-2472. doi: 10.1038/s41591-024-03092-6

The authors declare that there are no conflicts of interest present.